GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease
Open Access
- 13 July 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-10
Abstract
Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney events (MAKEs) in type 2 diabetes patients with acute kidney disease (AKD). Utilizing global data from the TriNetX database (2002/09/01-2022/12/01) and propensity score matching, we compare 7511 GLP-1 RAs users to non-users among 165,860 AKD patients. The most common causes of AKI are sepsis (55.2%) and cardiorenal syndrome (34.2%). After a median follow-up of 2.3 years, GLP-1 RAs users exhibit reduced risks of mortality (adjusted hazard ratio [aHR]: 0.57), MACEs (aHR: 0.88), and MAKEs (aHR: 0.73). External validation in a multicenter dataset of 1245 type 2 diabetes patients with AKD supports the favorable outcomes. These results emphasize the potential of GLP-1 RAs in individualized treatment for this population.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (109-2321-B-182-001)
- Ministry of Health and Welfare, Taiwan | Health Promotion Administration, Ministry of Health and Welfare (MOHW112-TDU-B-212-144005)
- Chang Gung Medical Foundation (CMRPG-2K0091)
This publication has 56 references indexed in Scilit:
- Recovery Dynamics and Prognosis After Dialysis for Acute Kidney InjuryJAMA Network Open, 2024
- Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney DiseaseJAMA Network Open, 2024
- Pleiotropic effects of GLP‐1 receptor agonists on peripheral artery disease: Is there any hope?Diabetes/Metabolism Research and Reviews, 2023
- Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney DiseaseJAMA Network Open, 2022
- Renal protection with glucagon-like peptide-1 receptor agonistsCurrent Opinion in Pharmacology, 2020
- The Chang Gung Research Database—A multi‐institutional electronic medical records database for real‐world epidemiological studies in TaiwanPharmacoepidemiology and Drug Safety, 2019
- Long-term Sustainability of Diabetes Prevention ApproachesJAMA Internal Medicine, 2017
- Linking acute kidney injury to chronic kidney disease: the missing linksJournal Of Nephrology, 2016
- The Cardiovascular Biology of Glucagon-like Peptide-1Cell Metabolism, 2016
- Cardiovascular and hemodynamic effects of glucagon-like peptide-1Reviews in Endocrine and Metabolic Disorders, 2014